Forlong Biotechnology

Based in Suzhou, China, and founded in 2019 by Dong Wei(CEO) and co-founder Yanling Wu, Ji En and Tianlei Ying , Suzhou Forlong Biotechnology Co. , Ltd. , trading as Forlong Biotechnology, is a clinical-stage biotechnology company focusing on the development of next-generation cytokine drugs. In May 2026, Forlong Biotechnology raised CNY 120 million pre-series B funding co-led by Fudan Science Park Capital and an investor, with participation from Changshu Guofa Venture Capital, Kunsheng Relay Fund and other investors.

The company's core pipeline FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein that exerts anti-tumor effects by activating NK cells and memory T cells. In the indication of non-muscle-invasive bladder cancer (NMIBC), it has entered Phase II clinical trials in combination with BCG, and preliminary data show its potential as a biochemical infusion protein (BIC). The company's revenue is generated by developing engineered therapeutic cytokine combinations that target different stages of the cancer-immune cycle to treat cancer. The company will use the latest funding to advance FL115, an IL-15 superagonist, into the pivotal clinical stage, and FL116, a PD-1/IL-18 bispecific, into clinic.